OBJECTIVE: To estimate whether metformin use by ovarian cancer patients with type II diabetes was associated with improved survival. METHODS: We reviewed the effect of diabetes and diabetes medications on ovarian cancer treatment and outcomes in a single-institution retrospective cohort. Inclusion criteria were International Federation of Gynecology and Obstetrics stage I-IV epithelial ovarian, fallopian, or peritoneal cancer. Exclusion criteria were noninvasive pathology or nonepithelial malignancies. The primary exposures analyzed were history of type II diabetes and diabetes medications. The primary outcomes were progression-free and overall ovarian cancer survival. RESULTS: Of the 341 ovarian cancer patients included in the study, 297 did not have diabetes, 28 were type II diabetic patients who did not use metformin, and 16 were type II diabetic patients who used metformin. The progression-free survival at 5 years was 51% for diabetic patients who used metformin compared with 23% for the nondiabetic patients and 8% for the diabetic patients who did not use metformin (P=.03). The overall survival at 5 years was 63%, 37%, and 23% for the diabetic patients who used metformin, the nondiabetic patients, and the diabetic patients who did not use metformin, respectively (P=.03). The patients with diabetes received the same treatment for ovarian cancer as the patients without diabetes. The association of metformin use and increased progression-free survival, but not overall survival, remained significant after controlling for standard clinicopathologic parameters. CONCLUSION: In this ovarian cancer cohort, the patients with type II diabetes who used metformin had longer progression-free survival, despite receiving similar treatment for ovarian cancer.
OBJECTIVE: To estimate whether metformin use by ovarian cancerpatients with type II diabetes was associated with improved survival. METHODS: We reviewed the effect of diabetes and diabetes medications on ovarian cancer treatment and outcomes in a single-institution retrospective cohort. Inclusion criteria were International Federation of Gynecology and Obstetrics stage I-IV epithelial ovarian, fallopian, or peritoneal cancer. Exclusion criteria were noninvasive pathology or nonepithelial malignancies. The primary exposures analyzed were history of type II diabetes and diabetes medications. The primary outcomes were progression-free and overall ovarian cancer survival. RESULTS: Of the 341 ovarian cancerpatients included in the study, 297 did not have diabetes, 28 were type II diabeticpatients who did not use metformin, and 16 were type II diabeticpatients who used metformin. The progression-free survival at 5 years was 51% for diabeticpatients who used metformin compared with 23% for the nondiabeticpatients and 8% for the diabeticpatients who did not use metformin (P=.03). The overall survival at 5 years was 63%, 37%, and 23% for the diabeticpatients who used metformin, the nondiabeticpatients, and the diabeticpatients who did not use metformin, respectively (P=.03). The patients with diabetes received the same treatment for ovarian cancer as the patients without diabetes. The association of metformin use and increased progression-free survival, but not overall survival, remained significant after controlling for standard clinicopathologic parameters. CONCLUSION: In this ovarian cancer cohort, the patients with type II diabetes who used metformin had longer progression-free survival, despite receiving similar treatment for ovarian cancer.
Authors: Gordon J S Rustin; Michael Quinn; Tate Thigpen; Andreas du Bois; Eric Pujade-Lauraine; Anders Jakobsen; Elizabeth Eisenhauer; Satoru Sagae; Kathryn Greven; Ignace Vergote; Andres Cervantes; Jan Vermorken Journal: J Natl Cancer Inst Date: 2004-03-17 Impact factor: 13.506
Authors: Dorothee M Baur; Jens Klotsche; Ole-Petter R Hamnvik; Caroline Sievers; Lars Pieper; Hans-Ulrich Wittchen; Günter K Stalla; Roland M Schmid; Stefanos N Kales; Christos S Mantzoros Journal: Metabolism Date: 2010-11-16 Impact factor: 8.694
Authors: Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee Journal: CA Cancer J Clin Date: 2010-06-16 Impact factor: 508.702
Authors: Bolin Liu; Zeying Fan; Susan M Edgerton; Xin-Sheng Deng; Irina N Alimova; Stuart E Lind; Ann D Thor Journal: Cell Cycle Date: 2009-07-21 Impact factor: 4.534
Authors: I Ben Sahra; K Laurent; A Loubat; S Giorgetti-Peraldi; P Colosetti; P Auberger; J F Tanti; Y Le Marchand-Brustel; F Bost Journal: Oncogene Date: 2008-01-21 Impact factor: 9.867
Authors: Sao Jiralerspong; Shana L Palla; Sharon H Giordano; Funda Meric-Bernstam; Cornelia Liedtke; Chad M Barnett; Limin Hsu; Mien-Chie Hung; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Donald M Lamkin; Douglas R Spitz; Mian M K Shahzad; Bridget Zimmerman; Daniel J Lenihan; Koen Degeest; David M Lubaroff; Eileen H Shinn; Anil K Sood; Susan K Lutgendorf Journal: Cancer Date: 2009-03-01 Impact factor: 6.860
Authors: Peter C Hart; Hilary A Kenny; Niklas Grassl; Karen M Watters; Lacey M Litchfield; Fabian Coscia; Ivana Blaženović; Lisa Ploetzky; Oliver Fiehn; Matthias Mann; Ernst Lengyel; Iris L Romero Journal: Cell Rep Date: 2019-12-17 Impact factor: 9.423